Gene · 81027
TUBB1: tubulin beta 1 class VI
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TUBB1: tubulin beta 1 class VI. Genes, record 81027. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/81027
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9H4B7 | Tubulin beta-1 chain | 451 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents23
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 68524 | Q9H4B7 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 93576 | Q9H4B7 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 196547 | Q9H4B7 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 12150 | Q9H4B7 | Espacenet |
| WO 2019229113 A1 | 2019-12-05 | 2 | Q9H4B7 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 248959 | Q9H4B7 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 248959 | Q9H4B7 | Espacenet |
| JP 2016507723 A | 2016-03-10 | 179 | Q9H4B7 | Espacenet |
| EP 2926138 A2 | 2015-10-07 | 179 | Q9H4B7 | Espacenet |
| KR 1020150090240 A | 2015-08-05 | 179 | Q9H4B7 | Espacenet |
1 to 10 of 23
See all 23 patentsDrugs91
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ABT-751 | CHEMBL20684 | Tubulin beta inhibitor | INHIBITOR | ChEMBL |
| AGS-16C3F | CHEMBL4594455 | Tubulin disrupting agent | DISRUPTING AGENT | ChEMBL |
| ANETUMAB RAVTANSINE | CHEMBL2109629 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANG1005 | CHEMBL1089636 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANVATABART OPADOTIN | CHEMBL4297892 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| APRUTUMAB IXADOTIN | CHEMBL4650293 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ASG-5ME | CHEMBL2109574 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AVE-9633 | CHEMBL2109266 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AZINTUXIZUMAB VEDOTIN | CHEMBL4297859 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| BELANTAMAB MAFODOTIN | CHEMBL4298209 | Tubulin inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 91
See all 91 drugsTrials8,740
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | PACLITAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07602907 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601737 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601178 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07599163 | PACLITAXEL | ClinicalTrials.gov | ||
| NCT07595770 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07594548 | PACLITAXEL | PHASE1 | ClinicalTrials.gov | |
| NCT07591467 | DOCETAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07589972 | VINORELBINE | ClinicalTrials.gov | ||
| NCT07588698 | VINCRISTINE SULFATE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 8,740
See all 8,740 trialsNIH grants474
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TUBB1 papers | Newest fiscal year |
|---|---|---|---|
| ZIAHL006170 | Cardiovascular Genomics and Bioinformatics projects | 3 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 2 | 2025 |
| R01CA240981 | Harnessing E3 Ligases for Cancer Therapy | 2 | 2025 |
| R01HL086694 | From GWAS loci to blood pressure genes, variants & mechanisms - Renewal | 2 | 2025 |
| ZIAHD008765 | Microtubule regulation by isotype expression, post translational modification, and by small molecules. | 2 | 2025 |
| I01CX001696 | Platelet Reprogramming During Inflammation | 1 | 2025 |
| I01CX002422 | Investigate the mechanism of autoreactive B cell-mediated immunological failure despite virologic suppression in HIV-infected individuals on antiretroviral therapy | 1 | 2025 |
| K12HD000850 | Pediatric Scientist Development Program | 1 | 2025 |
| KL2TR002379 | Institutional Career Development Core | 1 | 2025 |
1 to 10 of 474Source NIH's project files
See all 474 nih grantsPapers625
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Effects of Mebendazole and Flutamide Combination in Prostate Cancer Cell Lines: a Comprehensive in Vitro Analysis. | Cell Physiol Biochem | 2026 | 42675957 | PubTator, text mining | PubMed |
| Clonal lineage tracing of innate immune cells in human cancer. | Cancer Cell | 2026 | 42242233 | PubTator, text mining | PubMed |
| A Novel TUBB1 p.E158del Variant Causes Inherited Macrothrombocytopenia via Impaired Microtubule Assembly. | Int J Lab Hematol | 2026 | 42191667 | PubTator, text mining | PubMed |
| Architects of the Developing Brain: Cytoskeleton-Organizing Molecules in Neurodevelopmental Disorders. | Cells | 2026 | 41892327 | PubTator, text mining | PubMed |
| Co-inheritance of ITGA2B and TUBB1 variants in a family reveals distinct genetic contributions to platelet dysfunction. | Br J Haematol | 2026 | 41881807 | PubTator, text mining | PubMed |
| B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy. | Oncoimmunology | 2026 | 41792971 | PubTator, text mining | PubMed |
| TCL1A mediates DNA methylation defects in recurrent hydatidiform mole with NLRP7 pathogenic variants. | Nat Commun | 2026 | 41786744 | PubTator, text mining | PubMed |
| Differentially expressed proteins in plasma-derived extracellular vesicles from chronic myeloid leukemia patients. | Front Genet | 2026 | 41773228 | PubTator, text mining | PubMed |
| A molecular and spatial resource defining tubulin isotype organization during corneal development. | bioRxiv | 2026 | 41756856 | PubTator, text mining | PubMed |
| Clinical parameters and emerging biomarkers of partial remission in pediatric type 1 diabetes: a systematic review. | Front Endocrinol (Lausanne) | 2026 | 41737050 | PubTator, text mining | PubMed |
1 to 10 of 625
See all 625 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/81027
GET https://conductscience.org/api/genes/v1/81027/patents?page=2